Media appearances connected to work with PrEP4All:

STAT, “With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake.” (May 5, 2020)

TheBody, “PrEP Advocates Call New Gilead Patent Suit Against HHS a ‘Distraction.’” (May 4, 2020)

Bloomberg Law, “Facebook Ads Cause Patients to Stop, Switch HIV Prevention Drug.”  (December 16, 2019)

The Advocate, “PrEP4All Claims Gilead Held Back Safer HIV Drug.” (December 5, 2019)

Washington Post, “Gilead delayed safer HIV drug to extend monopoly profits, advocates allege.”  (December 5, 2019)

Modern Healthcare, “Gilead pledges to donate Truvada despite HHS patent lawsuit.”  (November 7, 2019)

NBC News, “U.S. sues Gilead, claiming it owns HIV PrEP patent.”  (November 7, 2019)

Financial Times, “Gilead did not seek US exclusivity on PrEP with Truvada.” (August 18, 2019)

STAT, “HHS gets a new HIV prevention patent, but will the agency demand royalties from Gilead?” (July 2, 2019)

Bloomberg News, “Gilead’s $21,000 Drug Is Being Blamed for a Plateau in HIV Prevention.” (May 17, 2019)

Bloomberg Law, “HIV Pill Patent Gives Trump Team Leverage in Gilead Price Talks.”  (April 12, 2019)

STAT, “AIDS activists skewer CDC for conflicting stance on collecting HIV drug royalties.” (April 10, 2019)

Washington Post, “An HIV treatment cost taxpayers millions. The government patented it. But a pharma giant is making billions.” (March 26, 2019)

Media appearances connected to work with Charles Seife and Peter Lurie:

STAT, “Following court ruling, NIH warns drug and device companies to post missing trial data.”  (August 4, 2020)

Endpoints News, “Clinical trial sponsors have to disclose decade’s worth of unreleased data, federal judge rules.”  (February 26, 2020)

STAT, “Federal judge rules clinical trial sponsors must publish a decade’s worth of missing data.”  (February 25, 2020)

Other media appearances:

Politico, “Trump’s Wild West approach to virus cure-alls is a game-changer for drugmakers.” (April 17, 2020)

STAT, “Academics and consumer groups protest FDA plan to summarize review documents.” (August 29, 2019)